You are here
Modern medicine has traveled far enough along the road of personalized medicine that we have reached a crossroads between genomics and imaging. Rather than taking a turn at this important intersection, experts are calling on both disciplines to create a map of the vast heterogeneity of each individual tumor using a fleet of imaging techniques, including CT, MRI and PET.
The term radiogenomics is popularly used to describe the growing field of study at this cross-section of imaging-based molecular phenotyping and genetic assays derived from biopsy. Poring over the human genome and epigenetic switches has taken researchers into a new frontier of disease diagnosis, risk stratification, therapy assessment and prognostic medicine. However, the truth is that single biopsy assays are...